X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

SEA Stories

Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

Presented by: Bayer
Sponsored by: Dendreon and Janssen Oncology
In-Kind Sponsor: Los Padres

Guest Speakers:

  • Dr. Edwin Morales – Urology Specialist, San Antonio
  • Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
  • Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
  • Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health

View the full video by clicking on the image below; or scroll down to access links to short video segments about specific content presented at the event.

Click any link listed below to go straight to that segment of the video:

  • 0:01 – Introduction – Terri Likowski, Us TOO Program Director – Support Group Services
  • 0:50 – Johnny Staha – Support Group Leader – San Antonio, TX
  • 1:07 – Chuck Strand – CEO, Us TOO International
  • 3:04 – Intro to Dr. Juan A. Reyna
  • 4:44 – Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
  • 10:00 – Intro to Dr. Edwin Morales
  • 10:56 – Dr. Edwin Morales – Urology Specialist, San Antonio
  • 11:01 – Prostate Cancer Overview, Definitions, Terms
  • 11:52 – Biochemical Recurrence
  • 14:29 – (Non) Metastatic Castrate Resistant Prostate Cancer
  • 17:52 – The Androgen Receptor Axis
  • 20:47 – Androgen Deprivation Therapy
  • 21:17 – After ADT
  • 23:00 – Options for Rising PSA After CAB/AAW
  • 23:44 – Asymptomatic Non – Metastatic Castrate Resistant Prostate Cancer
  • 26:36 – Options for Asymptomatic Non – Metastatic Castrate Resistant Prostate Cancer
  • 32:16 – The "New" Natural History of Prostate Cancer
  • 33:45 – Intro to Dr. Vijay Gunuganti
  • 34:26 – Dr. Vijay Gunuganti – Oncologist at Texas Oncology
  • 35:03 – Lifetime Probability of Developing Cancer
  • 36:07 – Multidisciplinary Team Approach to PCa Management
  • 37:02 – Treatment for CRPC
  • 37:24 – Early Metastatic Prostate Cancer or Hormone Sensitive Prostate Cancer
  • 37:58 – The CHAARTED Hypotheses
  • 38:45 – LATITUDE Trial
  • 39:19 – STAMPEDE Trial
  • 39:33 – Results of Androgen Removal
  • 40:17 – Castrate Resistant Metastatic Prostate Cancer or Hormone Refractory Prostate Cancer
  • 40:59 – Enzalutamide
  • 41:47 – Abiraterone
  • 42:28 – Metastatic Bone Lesions
  • 43:39 – Xofigo
  • 44:10 – Phase III ALSYMPCA Study Design: Patient Eligibility
  • 45:38 – Treatment of Symptomatic, Hormone Refractory Metastatic Disease with Chemotherapy
  • 46:52 – Side Effects of Chemotherapy
  • 48:07 – Currently Approved Therapy for Advanced Prostate Cancer
  • 49:48 – Intro to Dr. Michael Liss
  • 50:52 – Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
  • 51:56 – Screening, PSA Testing, At – Risk Groups
  • 54:35 – African American Men, Family History
  • 55:18 – Individualized Risk Assessment Approach, Shared Decision Making
  • 57:20 – Hereditary Prostate Cancer
  • 58:43 – BRCA
  • 58:54 – Genetics – Risk Using SNPs
  • 59:50 – Functional vs. Non – Functional Genes
  • 1:00:31 – Prostate Genetic Score
  • 1:01:04 – Genomics for Treatment Decisions
  • 1:04:56 – Future of Clinical Trials
  • 1:06:11 – Prostate Imaging – MRI
  • 1:08:29 – Software Detection Technologies, Restricted Spectrum Imaging
  • 1:09:08 – PET/CT Imaging
  • 1:10:32 – Oligometastatic Prostate Cancer Clinical Trials
  • 1:12:35 – Q&A